ArticleEuropean radiology2024
Discrimination between human epidermal growth factor receptor 2 (HER2)-low-expressing and HER2-overexpressing breast cancers: a comparative study of four MRI diffusion models.
Article in European radiology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 39 citations in OpenAlex.
- Navigating the diagnostic 'gray zone': prospective evaluation of an integrated MRI-Biomarker model for renal allograft triage.Annals of medicine · 2026Article
- Diagnostic value of a multiparametric magnetic resonance imaging-based nomogram incorporating apparent diffusion coefficient in preoperative differentiation of phyllodes tumors from breast cancer: a retrospective study.Quantitative imaging in medicine and surgery · 2026Article
- Article
- Added value of intravoxel incoherent motion histogram analysis in differentiating HER2-zero, HER2-low, and HER2-positive breast cancer.La Radiologia medica · 2026Article
- The value of non-enhanced magnetic resonance imaging based on T2-weighted imaging and apparent diffusion coefficient in the study of three-tiered HER2 status in patients with breast cancer.Quantitative imaging in medicine and surgery · 2026Article
- Comparative analysis of the diagnostic value of dynamic contrast-enhanced magnetic resonance imaging kinetic heterogeneity and apparent diffusion coefficient for grading invasive breast cancer.Diagnostic and interventional radiology (Ankara, Turkey) · 2026Article
- Distinguishing Ki67 stratification expression in ER-positive/HER2-negative breast cancers: comparison of advanced MRI diffusion models.BMC medical imaging · 2026Article
- Precise zonal diagnosis: multi-b-value DWI model reveals differential predictors of clinically significant prostate cancer in peripheral and transition zones.Insights into imaging · 2026Article
- Evaluating the efficacy of virtual magnetic resonance elastography and continuous-time random walk models in predicting clinically significant prostate cancer.Abdominal radiology (New York) · 2026Article
- Noninvasive stratification of HER2 status in breast cancer using multiparametric DECT: a prospective cohort study.International journal of surgery (London, England) · 2026Article
- Quantitative MRI mapping parameters to differentiate HER2-positive and HER2-low breast cancer.Quantitative imaging in medicine and surgery · 2026Article
- Non-Gaussian diffusion MRI models for preoperative assessment of microvascular invasion in hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
- Whole-lesion histogram analysis of multi-model diffusion-weighted imaging for characterization and molecular classification of breast lesions.La Radiologia medica · 2026Article
- Non-Gaussian diffusion MRI using CTRW and FROC models for early treatment response assessment in nasopharyngeal carcinoma.BMC medical imaging · 2026Article
- Machine Learning Model Based on Multiparametric MRI for Distinguishing HER2 Expression Level in Breast Cancer.Current oncology (Toronto, Ont.) · 2026Article
- Multiparametric MRI-based nomogram integrating clinicopathological factors for predicting HER2 expression status in breast cancer.Frontiers in oncology · 2026Article
- Article
- HER2-Low Breast Cancer at the Interface of Pathology and Technology: Toward Precision Management.Biomedicines · 2025Review
- Automated machine learning-based unenhanced radiomics for identification of HER2-low breast cancers using diffusion-weighted imaging.BMC cancer · 2025Article
- Noninvasive grading of renal interstitial fibrosis and prediction of annual renal function loss in chronic kidney disease: the optimal solution of seven MR diffusion models.Renal failure · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
Abstract
objectivesTo determine the value of conventional DWI, continuous-time random walk (CTRW), fractional order calculus (FROC), and stretched exponential model (SEM) in discriminating human epidermal growth factor receptor 2 (HER2) status of breast cancer (BC).
methodsThis prospective study included 158 women who underwent DWI, CTRW, FROC, and SEM and were pathologically categorized into the HER2-zero-expressing group (n = 10), HER2-low-expressing group (n = 86), and HER2-overexpressing group (n = 62). Nine diffusion parameters, namely ADC, α
resultsThe estrogen receptor (ER) status, progesterone receptor (PR) status, and tumor size differed between HER2-low-expressing and HER2-overexpressing groups (p < 0.001 to p = 0.009). The α
conclusionsThe α CLINICAL RELEVANCE STATEMENT: Human epidermal growth factor receptor 2 (HER2)-low-expressing breast cancer (BC) might also benefit from the HER2-targeted therapy. Prediction of HER2-low-expressing BC or HER2-overexpressing BC is crucial for appropriate management. Advanced continuous-time random walk diffusion MRI offers a solution to this clinical issue. KEY POINTS: • Human epidermal receptor 2 (HER2)-low-expressing BC had lower α
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.